- Home
- Therapeutics
- Urology
Urology
Proactive and tailored patient recruitment strategy to ensure achievement of your patient enrolment goals and study timelines
Diseases of the kidney and urinary tract account for approximately 830,000 deaths and 18,467,000 disability-adjusted life years annually.
Such conditions rank 12th among causes of death (1.4 percent of all deaths) and 17th among causes of disability (1.0 percent of all disability-adjusted life years) worldwide. Common Urinary tract indications like Benign prostatic hyperplasia (BPH), Incontinence and Overactive Bladder are of high significance with considerable social and economic impact for both the individual and the society.
At ICON, we have a thorough understanding of specific needs and challenges encountered in patients suffering from urology diseases and we will offer you a proactive and tailored patient recruitment strategy to ensure achievement of your patient enrolment goals and study timelines. Our global team of medical experts are committed to anticipating and overcoming the challenges to your drug development pipeline.
ICON experience in urology studies
-
32
Studies conducted -
8,100+
Patients involved -
2,300
Sites worldwide
We offer extensive global experience in program consultancy and multi-service studies, along with full-service clinical development program ownership.
ICON Urology experience covers the following indications:
- Benign Prostatic Hyperplasia/Hypertrophy (LUTS/BPH)
- Bladder Pain Syndrome
- Chronic Prostatitis/ Chronic Pelvic Pain Syndrome
- Overactive Bladder
- Nocturia
- Contraception/Endometriosis Pain
- Kidney/renal Diseases
ICON technology innovations
ICON combines best practice processes with innovative technology to deliver a customized solution for your urology portfolios.
FIRECREST, our industry leading digital solution for site training and communication supports study and site staff to manage and encourage patient participation and retention. Our FIRECREST team supported over 14 urology trials so far, covering all major urology indications
Our eTMF system provides remote access, which allows sponsors to maintain full oversight of the trial. With this technology, you can locate study documents with just a few clicks, and keep your notes within the eTMF.
We also have detailed understanding of the design requirements of PRO instruments used in Urology indications and support the design and implementation to optimize the quality of any patient reported outcome data.
FIRECREST Videos
The following videos, produced by FIRECREST look at Overactive Bladder [CK1] – BPH, Nocturnal Polyuria, and Interstitial Cystitis – Bladder Pain Syndrome.
In this section
-
Biosimilars
-
Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
- Endocrine & Metabolic Disorders
- Infectious Diseases
- Internal Medicine & Immunology
-
Medical Device
- Oncology
-
Paediatrics
- Rare & Orphan Diseases
- Vaccines
-
Women's Health
-
Therapeutics insights
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
-
Women's Health Insights
-
Oncology
- Paediatrics
-
Rare and orphan diseases
-
Pushing boundaries in idiopathic pulmonary fibrosis clinical research
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Pushing boundaries in idiopathic pulmonary fibrosis clinical research